CAR T-Cell Therapy Development Overview
Unlocking CAR T-Cell Therapy Development
Gene-modified cell therapy, specifically Chimeric Antigen Receptor (CAR) T cell therapy, is changing how cancer is treated. CAR T cell empowers the patient’s own immune cells to fight their cancer, providing an effective alternative to traditional cancer treatments and giving patients hope for a healthier life.
CAR T cell production is complex. Unlike traditional drugs, CAR T cells are living biological systems governed by rules that are not completely under our control. This creates new challenges in their development, validation, and implementation that could potentially influence their safety and efficacy. Further research and development are key to unlocking the full therapeutic potential of CAR T-cell therapy.
Bio-Rad is here to support you through the process of CAR T-cell therapy development. Our enhanced technologies for cell phenotyping, manufacturing, quality control, bioanalysis, and efficacy studies can help you bring more life-saving therapies to market.
CAR T-Cell Therapy Development Solutions
While CAR T-cell therapy offers a promising alternative to cancer treatments, it also poses several challenges for research and development. Using the proper tools can ensure the generation of safe, viable treatments. Bio-Rad offers solutions to support all the stages of research and CAR T-cell therapy production:
Discover novel targets and phenotype CAR T cells using custom antibodies and high-throughput flow cytometry.
Monitor production and maintain quality control with Droplet Digital PCR (ddPCR) Assays designed to quantify and detect T cell gene modification.
Perform bioanalysis and efficacy studies using specialized antibody reagents, flow cytometry, and ddPCR.